 |
Journal articles
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.
Bernard Royer
1, 2, 3, 4, *
Elsa Kalbacher
5
Sylvain Onteniente
4
Vincent Jullien
6, 7
Damien Montange
3, 4
Sarah Piedoux
4
Antoine Thiery-Vuillemin
5
Delphine Delroeux
8
Sébastien Pili-Floury
9
Emmanuel Guardiola
5
Marielle Combe
9, 10
Patrice Muret
1, 2, 3, 4
Virginie Nerich
11
Bruno Heyd
8
Bruno Chauffert
12
Jean-Pierre Kantelip
4
Xavier Pivot
1, 2, 3, 5
*
Corresponding author
Bernard Royer 1, 2, 3, 4
Correspondent author
Elsa Kalbacher 5
Author
Sylvain Onteniente 4
Author
Vincent Jullien 6, 7
Author
Damien Montange 3, 4
Author
Sarah Piedoux 4
Author
Antoine Thiery-Vuillemin 5
Author
Delphine Delroeux 8
Author
Sébastien Pili-Floury 9
Author
Emmanuel Guardiola 5
Author
Marielle Combe 9, 10
Author
Patrice Muret 1, 2, 3, 4
Author
Virginie Nerich 11
Author
Bruno Heyd 8
Author
Bruno Chauffert 12
Author
Jean-Pierre Kantelip 4
Author
Xavier Pivot 1, 2, 3, 5
Author
1
CICB - Centre d'Investigation Clinique de Besançon (France)
- EFS [Bourgogne-Franche-Comté] - Etablissement français du sang [Bourgogne-Franche-Comté] (1 Boulevard Fleming 25020 Besançon cedex - France)
- CHRU Besançon - Centre Hospitalier Régional Universitaire [Besançon] (France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : CIC1431 (101, rue de Tolbiac, 75013 Paris - France)
- UFC - Université de Franche-Comté (1 rue Goudimel 25030 Besançon cedex - France)
2
UFC - Université de Franche-Comté (1 rue Goudimel
25030 Besançon cedex - France)
3
RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (I.B.C.T.
Bâtiment Inserm
240 Route de Dole/Rue F. Dolto
25000 Besançon - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1098 (101, rue de Tolbiac, 75013 Paris - France)
- UFC - Université de Franche-Comté (1 rue Goudimel 25030 Besançon cedex - France)
- EFS [Bourgogne-Franche-Comté] - Etablissement français du sang [Bourgogne-Franche-Comté] (1 Boulevard Fleming 25020 Besançon cedex - France)
4
Laboratoire de Pharmacologie Clinique et Toxicologie [Besancon] (France)
- CHRU Besançon - Centre Hospitalier Régional Universitaire [Besançon] (France)
- Hôpital Jean Minjoz (France)
- UFC - Université de Franche-Comté (1 rue Goudimel 25030 Besançon cedex - France)
5
Service d'oncologie Médicale (France)
6
Service de pharmacologie (Paris - France)
- Hôpital Cochin [AP-HP] (27 Rue du Faubourg Saint-Jacques 75014 Paris - France)
- Hôpital Saint-Vincent de Paul (France)
- UPD5 - Université Paris Descartes - Paris 5 (12, rue de l'École de Médecine - 75270 Paris cedex 06 - France)
7
U1129 - Epilepsies de l'Enfant et Plasticité Cérébrale (149 Rue de Sèvres 75015 Paris - France)
- CEA - Commissariat à l'énergie atomique et aux énergies alternatives (Centre de Saclay Centre de Grenoble Centre de Cadarache etc - France)
- UPD5 - Université Paris Descartes - Paris 5 : UMR_S 1129 (12, rue de l'École de Médecine - 75270 Paris cedex 06 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1129 (101, rue de Tolbiac, 75013 Paris - France)
8
Service d'oncologie chirurgicale (Besançon - France)
9
Service d'anesthésie et soins intensifs (25000 Besançon - France)
10
Hôpital Jean Minjoz (France)
11
Service de pharmacie (Besançon - France)
Abstract : BACKGROUND: Intraperitoneal (IP) perioperative chemotherapy with cisplatin is an interesting option in ovarian cancer treatment. A combination of cisplatin with IP epinephrine (already shown to improve IP and decrease systemic platinum (Pt) exposure) was evaluated using a population pharmacokinetic analysis. METHODS: Data from 55 patients treated with cisplatin-based IP perioperative chemotherapy with (n=26) or without (n=29) epinephrine were analysed using NONMEM. RESULTS: Epinephrine halves clearance between peritoneum and serum (IPCL) and increases the Pt central volume of distribution, IP exposure and penetration in tissue. IPCL has a better predictive value than any other parameter with respect to renal toxicity. CONCLUSION: This confirms that IPCL could be useful in assessing renal toxicity. As IPCL is also linked to tissue penetration and IP exposure, it may be proposed as biomarker. In addition to a Bayesian estimation, we propose a single-sample calculation-way to assess it. Prospective studies are needed to validate IPCL as a biomarker in this context.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-00799502
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, March 12, 2013 - 12:15:00 PM
Last modification on : Monday, October 11, 2021 - 10:04:58 AM
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, March 12, 2013 - 12:15:00 PM
Last modification on : Monday, October 11, 2021 - 10:04:58 AM
Links full text
Identifiers
- HAL Id : inserm-00799502, version 1
- DOI : 10.1038/bjc.2011.557
- PUBMED : 22173671
Collections
INSERM | UNIV-FCOMTE | UMR645 | UNIV-PARIS5 | USPC | CEA | UNIV-PARIS | POLITIQUES-PUBLIQUES
Citation
Bernard Royer, Elsa Kalbacher, Sylvain Onteniente, Vincent Jullien, Damien Montange, et al.. Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.. BJC, 2012, 106 (3), pp.460-7. ⟨10.1038/bjc.2011.557⟩. ⟨inserm-00799502⟩